Free Trial
NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Price, News & Analysis

Leap Therapeutics logo
$3.74
-0.43 (-10.31%)
(As of 10/31/2024 ET)

About Leap Therapeutics Stock (NASDAQ:LPTX)

Key Stats

Today's Range
$3.61
$4.24
50-Day Range
$2.29
$4.61
52-Week Range
$1.32
$5.00
Volume
553,598 shs
Average Volume
235,906 shs
Market Capitalization
$95.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.40
Consensus Rating
Buy

Company Overview

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Leap Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
66th Percentile Overall Score

LPTX MarketRank™: 

Leap Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 406th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Leap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Leap Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Leap Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Leap Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Leap Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Leap Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Leap Therapeutics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Leap Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.43% of the float of Leap Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Leap Therapeutics has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Leap Therapeutics has recently decreased by 19.53%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Leap Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Leap Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.43% of the float of Leap Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Leap Therapeutics has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Leap Therapeutics has recently decreased by 19.53%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Leap Therapeutics has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Leap Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for LPTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Leap Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.30% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 30.46% of the stock of Leap Therapeutics is held by institutions.

  • Read more about Leap Therapeutics' insider trading history.
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

Leap Therapeutics Inc (5MC.MU)
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
3 Trending Biotech Penny Stocks
See More Headlines

LPTX Stock Analysis - Frequently Asked Questions

Leap Therapeutics' stock was trading at $4.15 on January 1st, 2024. Since then, LPTX shares have decreased by 9.9% and is now trading at $3.74.
View the best growth stocks for 2024 here
.

Leap Therapeutics, Inc. (NASDAQ:LPTX) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.10.

Shares of Leap Therapeutics reverse split on Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Leap Therapeutics' top institutional shareholders include Key Client Fiduciary Advisors LLC (1.26%).
View institutional ownership trends
.

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Vaxart (VXRT) and OPKO Health (OPK).

Company Calendar

Last Earnings
8/12/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.40
High Stock Price Target
$17.50
Low Stock Price Target
$5.50
Potential Upside/Downside
+178.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-81,410,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$2.35 per share

Miscellaneous

Free Float
24,218,000
Market Cap
$95.74 million
Optionable
Optionable
Beta
0.27
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:LPTX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners